Retatrutide
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 results generated strong interest, but investigational status means it should be treated as pipeline research, not consumer access guidance.
CagriSema, amycretin, and amylin combinations
CagriSema combines GLP-1 and amylin-pathway activity. Amycretin and other amylin-plus-incretin approaches are adjacent because they signal a move toward multi-pathway satiety medicines. Public data makes the category important to watch, but approval status, label language, real-world tolerability, and access remain key unknowns until regulatory review and broader use.
Oral and next-generation formats
Orforglipron, higher-dose oral semaglutide programs, and other oral incretins may compete on convenience, manufacturing scale, adherence, access, metabolic outcomes, cardiovascular data, and durability. The Glow Diary will track what changes without presenting pipeline products as available care.
MASH and metabolic-liver crossover
Mazdutide, pemvidutide, survodutide, and other glucagon or incretin-adjacent programs also matter because metabolic therapy is expanding beyond weight-only headlines into liver fat, cardiometabolic risk, and obesity complications. These topics need careful claim separation: a MASH or liver-fat endpoint is not the same as an obesity approval, and vice versa.
Sources and further reading
These links are included to make the evidence trail visible. They are not sponsor links and do not replace product-specific medical advice.